二重特異性抗体市場- 世界の産業規模、シェア、動向、市場機会、予測、2018年-2028年、適応症別、地域別

世界の二重特異性抗体市場は2022年に56億7,000万米ドルと評価され、2028年までのCAGRは9.43%で、予測期間中に目覚ましい成長を遂げると予測されています。

世界の二重特異性抗体市場は、バイオ医薬品業界において著しい成長と技術革新を遂げています。二重特異性抗体は、2つの異なる抗原を同時に標的とするように設計された治療用タンパク質の一種であり、がんや自己免疫疾患を含む様々な疾患の治療に独自のアプローチを提供します。

バイオテクノロジーの進歩により、科学者は二重特異性抗体をかつてない精度で精密に設計できるようになっています。この精度は、二重特異性抗体の特徴である2つの異なる分子や細胞を同時に標的とする抗体の設計に不可欠です。組換えDNA技術やCRISPR-Cas9遺伝子編集などの高度な技術を用いることで、研究者は絶妙な特異性を持つ二重特異性抗体を構築することができ、その治療の可能性を高めることができます。

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 二重特異性抗体の世界市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 適応症別（がん、炎症性疾患、自己免疫疾患、その他）
  • 地域別
  • 企業別（2022年）
• 製品市場マップ
  • 適応症別
  • 地域別

第6章 北米の二重特異性抗体市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 適応症別
  • 国別
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州の二重特異性抗体市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 適応症別
  • 国別
• 欧州国別分析
  • ドイツ
  • 英国
  • フランス
  • イタリア
  • スペイン

第8章 アジア太平洋地域の二重特異性抗体市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 適応症別
  • 国別
• アジア太平洋地域：国別分析
  • 中国
  • 日本
  • インド
  • オーストラリア
  • 韓国

第9章 南米の二重特異性抗体市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 適応症別
  • 国別
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカの二重特異性抗体市場展望

• 市場規模・予測
  • 金額別
• 市場シェアと予測
  • 適応症別
  • 国別
• MEA：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦
  • クウェート

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の展開
• 合併・買収
• 製品発表

第13章 ポーターのファイブフォース分析

• 業界内の競合
• 新規参入の可能性
• サプライヤーの力
• 顧客の力
• 代替品の脅威

第14章 競合情勢

• Business Overview
• Product Offerings
• Recent Developments
• Financials（As Reported）
• Key Personnel
• SWOT Analysis
  • Amgen Inc
  • Roche Holding AG
  • Genentech Inc
  • Akeso Inc
  • Janssen Pharmaceuticals Inc
  • Taisho Pharmaceutical Co Ltd
  • Immunocore Ltd

第15章 戦略的提言

第16章 調査会社について・免責事項

Global Bispecific Antibodies Market has valued at USD 5.67 billion in 2022 and is anticipated to project impressive growth in the forecast period with a CAGR of 9.43% through 2028. The global bispecific antibodies market has been witnessing significant growth and innovation in the biopharmaceutical industry. Bispecific antibodies are a class of therapeutic proteins designed to simultaneously target two different antigens, providing a unique approach to treating various diseases, including cancer and autoimmune disorders.

Key Market Drivers

Advancements in Biotechnology

Advancements in biotechnology have allowed scientists to precision-engineer bispecific antibodies with an unprecedented level of accuracy. This precision is essential for designing antibodies that can simultaneously target two distinct molecules or cells, a hallmark of bispecific antibodies. By using advanced techniques such as recombinant DNA technology and CRISPR-Cas9 gene editing, researchers can construct bispecific antibodies with exquisite specificity, enhancing their therapeutic potential.

Immunogenicity, or the propensity of a therapeutic molecule to trigger an immune response in the patient's body, is a significant concern in drug development. Biotechnological innovations have enabled the design of bispecific antibodies with reduced immunogenicity. This is achieved through methods like humanization, where the antibody structure is modified to closely resemble natural human antibodies, minimizing the risk of adverse reactions.

Biotechnology has paved the way for the development of advanced drug delivery systems that can optimize the pharmacokinetics and pharmacodynamics of bispecific antibodies. Nanotechnology, for instance, allows for the precise encapsulation and targeted release of bispecific antibodies, ensuring that they reach their intended targets more effectively. This can lead to improved therapeutic outcomes and a lower required dose.

The biotechnology industry has embraced high-throughput screening, automation, and computational modeling to expedite drug development processes. This includes the identification of potential drug candidates, optimization of antibody designs, and preclinical testing. These technological advancements have significantly shortened the time it takes to bring new bispecific antibodies from the laboratory to clinical trials.

Biotechnology has expanded the possibilities in terms of molecular targets for bispecific antibodies. Scientists can now identify and validate a broader range of target molecules, allowing for the development of bispecific antibodies targeting novel pathways and cellular components. This expanded target space opens doors to new therapeutic opportunities, driving growth in the market.

Advancements in biotechnology enable a more personalized approach to drug development and treatment. Bispecific antibodies can be customized to match the unique genetic and molecular profiles of individual patients. This tailoring of treatments, often referred to as precision medicine, maximizes therapeutic efficacy and minimizes adverse effects, making bispecific antibodies an attractive option for patients and healthcare providers.

Immunotherapy Revolution

Immunotherapy aims to harness the body's own immune system to combat diseases, particularly cancer. Bispecific antibodies play a critical role in this by acting as bridges between immune cells and target cells, thereby enhancing the immune system's ability to identify and destroy abnormal cells. This synergy between immunotherapy and bispecific antibodies is a driving force behind the market's growth.

One of the primary mechanisms of action for bispecific antibodies is their ability to target specific antigens present on tumor cells. By engaging both tumor cells and immune cells, these antibodies effectively "guide" the immune system to the site of the disease. This precise targeting results in fewer off-target effects and potentially higher treatment efficacy, making bispecific antibodies an attractive choice for immunotherapy.

Bispecific antibodies are designed to engage with T cells (T lymphocytes) and natural killer (NK) cells, which are pivotal components of the immune system. When these immune cells are recruited to the tumor site through bispecific antibodies, they become activated and unleash a targeted attack on the cancer cells. This mechanism is at the core of immunotherapy's success, and bispecific antibodies facilitate this process.

Cancer cells often employ various strategies to evade the immune system's detection. Bispecific antibodies can be engineered to counteract these evasion mechanisms. For instance, some bispecific antibodies block immune checkpoint proteins, preventing them from inhibiting the immune response. This helps the immune system overcome the tactics used by cancer cells to evade destruction.

While immunotherapy's initial success was in oncology, it has expanded its reach to treat other diseases, including autoimmune disorders and infectious diseases. Bispecific antibodies are adaptable to different therapeutic areas, making them versatile tools in the immunotherapy toolkit. As the application of immunotherapy diversifies, so does the demand for bispecific antibodies.

Immunotherapy often involves combination therapies that leverage the synergy of multiple treatment modalities. Bispecific antibodies are well-suited for combination approaches, as they can be combined with other immunotherapies, chemotherapy, or targeted therapies. These combinations enhance treatment efficacy and open new avenues for clinical research, contributing to market growth.

Expanding Therapeutic Applications

One of the most prominent areas of therapeutic application for bispecific antibodies is oncology. The market has witnessed a surge in the development of bispecific antibodies designed to treat various types of cancer. These antibodies target specific antigens on cancer cells, while simultaneously engaging the patient's immune system to mount a robust attack. As our understanding of cancer biology grows, so does the potential for the development of bispecific antibodies for different cancer subtypes.

Bispecific antibodies are increasingly being explored as potential treatments for autoimmune diseases. Conditions like rheumatoid arthritis, multiple sclerosis, and lupus involve an overactive immune response targeting healthy tissues. Bispecific antibodies can be engineered to modulate the immune system's activity, suppressing harmful immune reactions while leaving the rest of the immune response intact. This holds promise for improving the lives of patients with autoimmune disorders.

Infectious diseases have presented a global health challenge, and bispecific antibodies are emerging as a viable therapeutic option. Bispecific antibodies can be designed to neutralize viruses, such as HIV and COVID-19, by simultaneously binding to viral particles and immune cells. This dual-action approach enhances the body's ability to eliminate infection, making bispecific antibodies a valuable tool in infectious disease management.

The potential therapeutic applications of bispecific antibodies extend to neurological disorders. Conditions like Alzheimer's disease and Parkinson's disease involve complex molecular mechanisms. Bispecific antibodies can be engineered to target specific proteins or aggregates associated with these disorders, offering a novel approach to slowing disease progression or mitigating symptoms.

Bispecific antibodies are also being explored in the treatment of cardiovascular diseases. Researchers are investigating their role in targeting factors involved in atherosclerosis and thrombosis, aiming to reduce the risk of heart attacks and strokes. This application highlights the versatility of bispecific antibodies in addressing complex, non-cancerous conditions.

Pediatric diseases represent another area of potential growth for the bispecific antibodies market. By tailoring these molecules to address the unique needs of children, researchers can develop treatments for pediatric cancers, rare genetic disorders, and autoimmune conditions that affect children. This expansion into pediatric care holds promise for improving the quality of life for young patients.

Increasing Investment in Research and Development

Investment in R&D enables pharmaceutical and biotechnology companies to accelerate the discovery of novel bispecific antibody candidates. Researchers are continually exploring new targets and developing innovative antibody formats. With substantial funding, they can invest in high-throughput screening, computational modeling, and automation, all of which expedite the drug discovery process. This faster pace of discovery brings new therapies to the market more quickly.

Investment in R&D allows for the expansion of therapeutic indications for bispecific antibodies. While these molecules initially gained prominence in oncology, increased funding is driving research into their potential applications in autoimmune diseases, infectious diseases, and neurological disorders, among others. This diversification of therapeutic areas broadens the market and offers hope to patients suffering from a wide range of conditions.

The funding earmarked for R&D empowers researchers to invest in cutting-edge technologies for bispecific antibody engineering. This includes techniques such as recombinant DNA technology, CRISPR-Cas9 gene editing, and advanced protein engineering. With these tools, scientists can precisely design and optimize bispecific antibodies for enhanced efficacy and reduced immunogenicity.

Substantial R&D investment supports the progression of bispecific antibodies from the laboratory to clinical trials. These trials are essential for assessing safety and efficacy in human patients. Adequate funding ensures the efficient execution of clinical trials, covering patient recruitment, data collection, and analysis. Positive clinical trial outcomes attract further investment and contribute to market growth.

Increased investment in R&D empowers the biopharmaceutical industry to tackle unmet medical needs more effectively. Conditions with limited treatment options or high mortality rates, such as rare diseases and aggressive cancers, benefit from the development of innovative bispecific antibody therapies. This focus on unmet needs helps attract funding and drive market growth.

Key Market Challenges

Complex Design and Manufacturing

One of the primary challenges in the bispecific antibodies market is the complexity of their design and manufacturing processes. Creating bispecific antibodies that can simultaneously bind to two distinct molecules or cells requires precise engineering. The intricacies of their structure can lead to manufacturing challenges, impacting scalability, production costs, and consistency in quality.

Immunogenicity

Immunogenicity, the tendency of therapeutic molecules to induce an immune response in patients, is a significant concern in the development of bispecific antibodies. The complex nature of bispecific antibodies can trigger immune reactions in some individuals, potentially leading to adverse effects or reduced therapeutic efficacy. Addressing and minimizing immunogenicity is an ongoing challenge.

Cost of Development and Production

Developing bispecific antibodies is an expensive endeavor. From research and development to clinical trials and commercial production, the costs can be substantial. Smaller biotechnology firms may struggle to secure the necessary funding for these endeavors, limiting their ability to compete in the market and leading to consolidation within the industry.

Key Market Trends

Diversification of Therapeutic Applications

While the initial success of bispecific antibodies was primarily seen in oncology, the market is diversifying rapidly. Emerging trends indicate a broader range of therapeutic applications, including autoimmune diseases, infectious diseases, and neurological disorders. This diversification is driven by ongoing research and a deeper understanding of disease mechanisms, enabling the development of bispecific antibodies tailored to specific conditions.

Novel Bispecific Antibody Formats

The development of novel bispecific antibody formats is a trend that promises to enhance therapeutic efficacy. Innovations such as single-chain bispecific antibodies and multispecific antibodies are gaining traction. These formats offer improved pharmacokinetics, reduced immunogenicity, and enhanced tissue penetration, leading to more effective treatments and expanded market opportunities.

T-cell Engaging Bispecific Antibodies

Bispecific antibodies designed to engage T cells are at the forefront of immunotherapy research. These antibodies redirect the patient's immune system to target cancer cells. Emerging trends suggest that T-cell engaging bispecific antibodies will continue to evolve, with a focus on improving safety profiles and reducing cytokine release syndrome, a common side effect.

Segmental Insights

Indication Insights

Based on the category of Indication, Cancer is poised to dominate the Global Bispecific Antibodies Market in 2022 for several compelling reasons. First and foremost, cancer remains one of the most prevalent and challenging diseases worldwide, driving continuous demand for innovative and effective treatments. Bispecific antibodies, with their unique ability to simultaneously target multiple cancer-specific antigens, offer a promising avenue for improved therapeutic outcomes. Additionally, ongoing advancements in biotechnology and immunotherapy research have led to the development of increasingly sophisticated bispecific antibody candidates, which are gaining traction in clinical trials. Furthermore, the rising investment in oncology research and the expanding patient pool in emerging markets contribute to the growth potential of this market segment. With the pressing need for more efficacious cancer therapies, bispecific antibodies are well-positioned to play a pivotal role in shaping the future of cancer treatment, solidifying their dominance in the Global Bispecific Antibodies Market.

Regional Insights

North America is poised to dominate the Global Bispecific Antibodies Market in 2022 for several compelling reasons. Firstly, the region boasts a robust pharmaceutical and biotechnology industry with a strong focus on research and development, particularly in the field of immunotherapy and oncology. This commitment to innovation has led to the emergence of cutting-edge bispecific antibody therapies, which are gaining significant traction. Secondly, North America benefits from a well-established healthcare infrastructure and a vast patient population, particularly in the United States, where cancer rates are high. This combination of research prowess and a sizable addressable market creates a favorable environment for the adoption and commercial success of bispecific antibody treatments. Additionally, regulatory agencies such as the FDA have been receptive to novel therapeutic approaches, expediting the approval process for these groundbreaking drugs. Given these factors, North America is poised to maintain its dominance in the Global Bispecific Antibodies Market for the foreseeable future.

Key Market Players

Amgen Inc

Roche Holding AG

Genentech Inc

Akeso Inc

Janssen Pharmaceuticals Inc

Taisho Pharmaceutical Co Ltd

Immunocore Ltd

Report Scope:

In this report, the Global Bispecific Antibodies Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Bispecific Antibodies Market, By Indication:

• Cancer
• Inflammatory & Autoimmune Disorders
• Others

Bispecific Antibodies Market, By Region:

• North America
• United States
• Canada
• Mexico
• Europe
• Germany
• United Kingdom
• France
• Italy
• Spain
• Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE
• Kuwait

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Bispecific Antibodies Market.

Available Customizations:

• Global Bispecific Antibodies market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Bispecific Antibodies Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
  • 5.2.2. By Region
  • 5.2.3. By Company (2022)
• 5.3. Product Market Map
  • 5.3.1. By Indication
  • 5.3.2. By Region

6. North America Bispecific Antibodies Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
  • 6.2.2. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Bispecific Antibodies Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Indication
  • 6.3.2. Canada Bispecific Antibodies Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Indication
  • 6.3.3. Mexico Bispecific Antibodies Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Indication

7. Europe Bispecific Antibodies Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
  • 7.2.2. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Bispecific Antibodies Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Indication
  • 7.3.2. United Kingdom Bispecific Antibodies Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Indication
  • 7.3.3. France Bispecific Antibodies Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Indication
  • 7.3.4. Italy Bispecific Antibodies Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Indication
  • 7.3.5. Spain Bispecific Antibodies Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Indication

8. Asia-Pacific Bispecific Antibodies Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
  • 8.2.2. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Bispecific Antibodies Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Indication
  • 8.3.2. Japan Bispecific Antibodies Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Indication
  • 8.3.3. India Bispecific Antibodies Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Indication
  • 8.3.4. Australia Bispecific Antibodies Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Indication
  • 8.3.5. South Korea Bispecific Antibodies Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Indication

9. South America Bispecific Antibodies Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
  • 9.2.2. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Bispecific Antibodies Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Indication
  • 9.3.2. Argentina Bispecific Antibodies Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Indication
  • 9.3.3. Colombia Bispecific Antibodies Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Indication

10. Middle East and Africa Bispecific Antibodies Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Indication (Cancer, Inflammatory & Autoimmune Disorders, Others)
  • 10.2.2. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Bispecific Antibodies Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Indication
  • 10.3.2. Saudi Arabia Bispecific Antibodies Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Indication
  • 10.3.3. UAE Bispecific Antibodies Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Indication
  • 10.3.4. Kuwait Bispecific Antibodies Market Outlook
    • 10.3.4.1. Market Size & Forecast
      • 10.3.4.1.1. By Value
    • 10.3.4.2. Market Share & Forecast
      • 10.3.4.2.1. By Indication

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Development
• 12.2. Mergers & Acquisitions
• 12.3. Product Launches

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Products

14. Competitive Landscape

• 14.1. Business Overview
• 14.2. Product Offerings
• 14.3. Recent Developments
• 14.4. Financials (As Reported)
• 14.5. Key Personnel
• 14.6. SWOT Analysis
  • 14.6.1. Amgen Inc
  • 14.6.2. Roche Holding AG
  • 14.6.3. Genentech Inc
  • 14.6.4. Akeso Inc
  • 14.6.5. Janssen Pharmaceuticals Inc
  • 14.6.6. Taisho Pharmaceutical Co Ltd
  • 14.6.7. Immunocore Ltd

15. Strategic Recommendations

16. About Us & Disclaimer